睿知中国医院研究地图
候选清单

济南山东第一医科大学

山东第一医科大学第一附属医院(山东省千佛山医院)

First Affiliated Hospital of Shandong First Medical University

在本站收录的 61 种疾病中,这家医院列在其中 30 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

山东第一医科大学第一附属医院(山东省千佛山医院)的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma6 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma32 篇牵头论文
  3. 胃癌Stomach cancer26 篇牵头论文
  4. 肺癌Lung cancer89 篇牵头论文牵头 4 项开放试验
  5. 胰腺癌Pancreatic cancer11 篇牵头论文
  6. 乳腺癌Breast cancer25 篇牵头论文
  7. 胶质瘤Glioma14 篇牵头论文
  8. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  9. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  10. 骨肉瘤Osteosarcoma3 篇牵头论文
  11. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  12. 多发性骨髓瘤Multiple myeloma2 篇牵头论文
  13. 淋巴瘤Lymphoma6 篇牵头论文
  14. 血友病 AHaemophilia A2 篇牵头论文
  15. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  16. 重症肌无力Myasthenia gravis11 篇牵头论文
  17. 烟雾病Moyamoya disease3 篇牵头论文
  18. 冠心病Coronary heart disease8 篇牵头论文
  19. 先天性心脏病Congenital heart disease5 篇牵头论文
  20. 脊柱侧弯Scoliosis3 篇牵头论文
  21. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis4 篇牵头论文
  22. 大动脉炎Takayasu arteritis1 篇牵头论文
  23. 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文
  24. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis1 篇牵头论文
  25. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
  26. 法布雷病Fabry disease1 篇牵头论文
  27. IgA 肾病IgA nephropathy1 篇牵头论文
  28. 戈谢病Gaucher disease0 篇牵头论文
  29. 成骨不全症Osteogenesis imperfecta1 篇牵头论文
  30. 遗传性血管性水肿Hereditary angioedema0 篇牵头论文

未列出的收录疾病:鼻咽癌、脊索瘤、胃肠道间质瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、肝豆状核变性、胆道闭锁、肝包虫病、脊髓性肌萎缩症、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、尼曼-匹克病 C 型、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.2%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 0020242025: 222025

济南有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题免疫治疗新辅助与综合治疗分子标志物与基因
论文中的科室肿瘤内科消化/肝病科普外/肝胆胰外科
牵头的论文6
  1. Efficacy and safety of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma patients with pathologic incomplete response after neoadjuvant immunochemotherapy: a retrospective cohort study.2025Frontiers in immunology免费全文
  2. The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: a real-world study.2025Frontiers in immunology免费全文
  3. RNF106 aggravates esophageal squamous cell carcinoma progression through LATS2/YAP axis.2023Archives of biochemistry and biophysics
  4. Immune checkpoint inhibitor induced colitis and arthritis: A case report.2023Medicine免费全文
  5. Clinicopathological and Prognostic Significance of SMYD3 in Human Cancers: A Systematic Review and Meta-analysis.2022Genetic testing and molecular biomarkers
  6. Upregulation of miR-1269 Contributes to the Progression of Esophageal Squamous Cell Cancer Cells and Is Associated With Poor Prognosis.2021Technology in cancer research & treatment免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC已终止NCT02721550研究中心IV期2016-08 启动
  2. A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC已终止NCT02721576研究中心IV期2016-07 启动
  3. A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC已完成NCT02721563研究中心IV期2016-02 启动
PubMed 以外找到的论文(未计入)8
  1. Adjuvant therapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: A retrospective study study.2025Journal of Clinical Oncology论文
  2. Failure patterns and the value of postoperative adjuvant radiotherapy in esophageal squamous cell carcinoma patients treated with neoadjuvant immunotherapy combined with chemotherapy.2025Journal of Clinical Oncology论文
  3. The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: A real-world study.2025Journal of Clinical Oncology论文
  4. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  5. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  6. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  7. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  8. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 32 篇,占 0.2%。

牵头论文
32
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 6620222023: 111120232024: 6620242025: 442025

济南有 6 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科病理/检验科肿瘤内科
牵头的论文32
  1. Radiomic Model Based on Multisequence MRI to Preoperative Predict Ki-67 Expression in Hepatocellular Carcinoma.2026Academic radiology
  2. Lightweight Spectral-MLP for Hyperspectral Differentiation of Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.2026Journal of biophotonics
  3. Efficacy and safety analysis of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors with or without microwave ablation for unresectable hepatocellular carcinoma: a retrospective, multice2025Frontiers in immunology免费全文
  4. Comparative diagnostic efficacy of 18F-FDG and FAPI PET/CT in primary liver cancers: A systematic review and meta-analysis.2025Journal of cancer research and therapeutics
  5. Characterization of T-Cell Receptor Profiles Predicts Survival Situation in Patients with Hepatocellular Carcinoma.2025Technology in cancer research & treatment免费全文
  6. Phthalate exposure and hepatocellular carcinoma: Unraveling mechanisms through network toxicology.2025Toxicology
  7. A Meta-Analysis of MiRNA-497 and Prognosis of Hepatocellular Carcinoma.2024Canadian journal of gastroenterology & hepatology免费全文
  8. Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  9. Is intravoxel incoherent motion magnetic resonance imaging useful for predicting hepatocellular cancer recurrence and invasion of the peritumoral zone after transarterial chemoembolization?2024Journal of cancer research and therapeutics
  10. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.2024Journal of nanobiotechnology免费全文
  11. Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma.2024Scientific reports免费全文
  12. High throughput sequencing reveals alterations in B cell receptor repertoires associated with the progression of hepatic cirrhosis to hepatocellular carcinoma.2024Tumori
  13. The lipid peroxidation-derived DNA adduct γ-OHPdG as a diagnostic and prognostic biomarker in hepatocellular carcinoma.2023Aging免费全文
  14. circFAM134B is a key factor regulating reticulophagy-mediated ferroptosis in hepatocellular carcinoma.2023Cell cycle (Georgetown, Tex.)免费全文
  15. Exosomal circTGFBR2 promotes hepatocellular carcinoma progression via enhancing ATG5 mediated protective autophagy.2023Cell death & disease免费全文
  16. ZNF8-miR-552-5p Axis Modulates ACSL4-Mediated Ferroptosis in Hepatocellular Carcinoma.2023DNA and cell biology
  17. Iron accumulation and lipid peroxidation: implication of ferroptosis in hepatocellular carcinoma.2023Frontiers in endocrinology免费全文
  18. Clinical and prognostic significance of CCPG1 in hepatocellular carcinoma.2023General physiology and biophysics
  19. Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review.2023Journal of cancer research and therapeutics
  20. Transmembrane protein 147, as a potential Sorafenib target, could expedite cell cycle process and confer adverse prognosis in hepatocellular carcinoma.2023Molecular carcinogenesis
  21. Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma.2023Oncology reports免费全文
  22. DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma.2023Scientific reports免费全文
  23. Laparoscopic versus open surgery for hepatic caudate lobectomy: a retrospective study.2023Surgical endoscopy
  24. Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study.2022BMC gastroenterology免费全文
  25. Targeting FAM134B-mediated reticulophagy activates sorafenib-induced ferroptosis in hepatocellular carcinoma.2022Biochemical and biophysical research communications
  26. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.2022Biochemical and biophysical research communications
  27. Depleting circ_0088364 restrained cell growth and motility of human hepatocellular carcinoma via circ_0088364-miR-1270-COL4A1 ceRNA pathway.2022Cell cycle (Georgetown, Tex.)免费全文
  28. The deubiquitinase USP7 regulates oxidative stress through stabilization of HO-1.2022Oncogene
  29. Highly expressed FAM189B predicts poor prognosis in hepatocellular carcinoma.2022Pathology oncology research : POR免费全文
  30. RNA binding protein DAZAP1 promotes HCC progression and regulates ferroptosis by interacting with SLC7A11 mRNA.2021Experimental cell research
  31. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.2021Medicine免费全文
  32. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma.2021Scientific reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.状态不明NCT06205732牵头方2024-01 启动
  2. Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma状态不明NCT06365034牵头方2024-03 启动
  3. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 26 篇,占 0.3%。

牵头论文
26
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 6620232024: 101020242025: 332025

济南有 7 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    发布
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  2. 正在招募
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    分期
    不分期
    开始
    2023-12
    发布
    登记号
    NCT06081647

    年龄 18 岁 至 60 岁(登记的条件)

    牵头:上海交通大学医学院附属仁济医院;另有 7 家列出的医院为研究中心上海、南京、南昌、杭州、济南

  3. 邀请入组
    An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
    分期
    未注明
    开始
    2025-10
    发布
    登记号
    NCT07274579

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院;另有 1 家列出的医院为研究中心广州、济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物化疗与综合治疗影像与人工智能
论文中的科室普外/肝胆胰外科肿瘤内科病理/检验科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文26
  1. Nanozymes induced Z-scheme Mn-BiVO4/Au/Bi2S3 heterostructure photoelectrochemical signal amplification for CA72-4 detection.2026Biosensors & bioelectronics
  2. Targeting drug-tolerant persister cells to overcome resistance in HER2-positive gastric cancer.2026Critical reviews in oncology/hematology
  3. Mendelian Randomization and Transcriptome Data Analysis Reveal Bidirectional Causal Relationships and Mechanisms between Type 2 Diabetes and Gastric Cancer.2025Current medicinal chemistry
  4. Analysis of shared pathogenic mechanisms and drug targets in myocardial infarction and gastric cancer based on transcriptomics and machine learning.2025Frontiers in immunology免费全文
  5. Exploring the regulatory mechanisms of paraptosis-related prognostic genes in gastric cancer using single-cell sequencing and transcriptome analysis.2025Scientific reports免费全文
  6. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.2024Cancer medicine免费全文
  7. Circular RNA Circ_0001322 inhibits gastric cancer progression by modulating the miR-1264/QKI axis and suppressing the Hedgehog pathway.2024Cellular and molecular biology (Noisy-le-Grand, France)
  8. Nomogram for predicting overall survival after curative gastrectomy using inflammatory, nutritional and pathological factors.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  9. Gentiopicroside inhibits the progression of gastric cancer through modulating EGFR/PI3K/AKT signaling pathway.2024European journal of medical research免费全文
  10. Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report.2024Frontiers in immunology免费全文
  11. Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.2024Frontiers in immunology免费全文
  12. Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer.2024Investigational new drugs
  13. Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.2024Journal of cancer research and therapeutics
  14. The E3 ligase TRIM7 suppresses the tumorigenesis of gastric cancer by targeting SLC7A11.2024Scientific reports免费全文
  15. Bile acids inhibit ferroptosis sensitivity through activating farnesoid X receptor in gastric cancer cells.2024World journal of gastroenterology免费全文
  16. DSC2 suppresses the growth of gastric cancer through the inhibition of nuclear translocation of γ-catenin and PTEN/PI3K/AKT signaling pathway.2023Aging免费全文
  17. A Novel Scoring System in Predicting Prognosis After Adjuvant FOLFOX Chemotherapy in Gastric Cancer.2023Cancer biotherapy & radiopharmaceuticals
  18. circSLC4A7 accelerates stemness and progression of gastric cancer by interacting with HSP90 to activate NOTCH1 signaling pathway.2023Cell death & disease免费全文
  19. Microdissection of cancer-associated fibroblast infiltration subtypes unveils the secreted SERPINE2 contributing to immunosuppressive microenvironment and immuotherapeutic resistance in gastric cancer: A large-scale study integrating bulk a2023Computers in biology and medicine
  20. Pseudoprogression during immunotherapy for gastric adenocarcinoma: A case report and literature review.2023Journal of cancer research and therapeutics
  21. Huntingtin-associated protein 1 is a potential tumor suppressor for gastric cancer.2023Molecular biology reports
  22. PADI4 promotes epithelial-mesenchymal transition(EMT) in gastric cancer via the upregulation of interleukin 8.2022BMC gastroenterology免费全文
  23. PRDX3 promotes resistance to cisplatin in gastric cancer cells.2022Journal of cancer research and therapeutics
  24. Investigating the effect of ARHGEF10L gene on tumor growth in gastric cancer in a nude mouse model using quantitative MRI parameters.2022Journal of cancer research and therapeutics
  25. MicroRNAs are involved in the development and progression of gastric cancer.2021Acta pharmacologica Sinica免费全文
  26. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.2021The British journal of radiologyRCT免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer Patients已完成NCT05638048牵头方(推断)不分期2022-07 启动
  2. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  3. An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma邀请入组NCT07274579研究中心2025-10 启动
  4. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure正在招募NCT06081647研究中心不分期2023-12 启动
  5. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer进行中,不再招募NCT05586061研究中心II期2023-02 启动
  6. Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy进行中,不再招募NCT05585580研究中心II期2023-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 89 篇,占 0.4%。

牵头论文
89
2021–2025 年
牵头试验
11
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 131320222023: 282820232024: 191920242025: 17172025

济南有 9 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
    分期
    III期
    开始
    2023-09
    发布
    登记号
    NCT06043973

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东第一医科大学第一附属医院(山东省千佛山医院)济南

  2. 正在招募
    Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
    分期
    II期
    开始
    2023-10
    发布
    登记号
    NCT06125041

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东第一医科大学第一附属医院(山东省千佛山医院)济南

  3. 正在招募
    Patient's Whole Process Follow-up Management(HOPE-1)
    分期
    未注明
    开始
    2022-05
    发布
    登记号
    NCT05339568

    年龄 18 岁 至 未注明(登记的条件)

    牵头:山东第一医科大学第一附属医院(山东省千佛山医院)济南

  4. 邀请入组
    Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
    分期
    未注明
    开始
    2025-03
    发布
    登记号
    NCT06883136

    年龄 60 岁 至 80 岁(登记的条件)

    牵头:山东第一医科大学第一附属医院(山东省千佛山医院)济南

  5. 正在招募
    Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
    分期
    未注明
    开始
    2025-02
    发布
    登记号
    NCT06809764

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 30 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、厦门、合肥、广州、杭州、武汉、沈阳、济南、深圳、石家庄、福州、郑州、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科病理/检验科放疗科
牵头的论文89
  1. Local control treatment for pulmonary metastases of colorectal cancer.2026Critical reviews in oncology/hematology
  2. Microwave Ablation Combined with Flt3L Provokes Tumor-Specific Memory CD8+ T Cells-Mediated Antitumor Immunity in Response to PD-1 Blockade.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Overdiagnosis and overtreatment of ground-glass nodule-like lung cancer.2025Asia-Pacific journal of clinical oncology
  4. Tumor treating fields enhance anti-PD therapy by improving CCL2/8 and CXCL9/CXCL10 expression through inducing immunogenic cell death in NSCLC models.2025BMC cancer免费全文
  5. Glimepiride overcomes acquired resistance to EGFR TKIs in lung cancer via the AMPK/ERK/MMP7 signaling pathway.2025Biochemical pharmacology
  6. Microwave ablation combined with immune checkpoint inhibitor enhanced the antitumor immune activation and memory in rechallenged tumor mouse model.2025Cancer immunology, immunotherapy : CII免费全文
  7. Therapeutic targeting of cGAS-STING pathway in lung cancer.2025Cell biology international
  8. Clinical efficacy and safety of immune checkpoint inhibitors plus anlotinib as secondline or subsequent therapy in extensive stage small cell lung cancer: a retrospective study.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  9. Complement Factor H Promotes the Growth of Lung Adenocarcinoma Cells through the JAK2/STAT3 Signaling Pathway.2025Current cancer drug targets
  10. Discovery of Multiple Effects of Reactive Oxygen Species on Lung Adenocarcinoma at the Single-cell and Bulk Tissue Levels.2025Current medicinal chemistry
  11. Rare recurrent multiple pulmonary sclerosing pneumocytoma with sarcomatoid features: A case report and literature review.2025Journal of cancer research and therapeutics
  12. Construction and application of a mortality risk prediction model for patients with lung squamous cell carcinoma: A competing risk analysis.2025Journal of cancer research and therapeutics
  13. Effectiveness and safety of percutaneous microwave ablation and radiofrequency ablation in the treatment of pulmonary metastasis: A systematic review and meta-analysis.2025Journal of cancer research and therapeutics
  14. Microwave ablation combined with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor treatment in EGFR -mutant advanced non-small cell lung cancer.2025Journal of cancer research and therapeutics
  15. Largest dimension of ground-glass nodule-like lung cancer: Comparison of computed tomography imaging and resected pathological specimens.2025Journal of cancer research and therapeutics
  16. Identifying circRNA-miRNA-mRNA Networks Associated with Osimertinib Resistance in Lung Adenocarcinoma by Analyzing Microarray Datasets.2025Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  17. Prediction model for growth trends of subpleural subsolid nodules using CT radiomics and radiological features.2025Scientific reports免费全文
  18. Predicting PD-L1 status in NSCLC patients using deep learning radiomics based on CT images.2025Scientific reports免费全文
  19. The Evaluation of Urinary HE4, CEA, ProGRP, CYFRA 21-1 and NSE in the Diagnosis of Lung Cancer.2024Annals of clinical and laboratory science
  20. Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  21. Effect of Sequence of Radiotherapy Combined With Immunotherapy on the Incidence of Pneumonitis in Patients With Lung Cancer: A Systematic Review and Network Meta-Analysis.2024Clinical lung cancer
  22. The Relationship between Quantitative Parameters of Dual-energy CT and HIF-1α Expression in Non-Small Cell Lung Cancer.2024Current medical imaging
  23. A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer.2024Frontiers in immunology免费全文
  24. Hydrodissection technique for pain relief during peri-microwave ablation in patients with subpleural non-small cell lung cancers.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  25. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.2024Investigational new drugs免费全文
  26. Successful treatment of epidermal growth factor receptor exon 19 deletion non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: A case report.2024Journal of cancer research and therapeutics
  27. Dihydroartemisinin ameliorates skeletal muscle atrophy in the lung cancer cachexia mouse model.2024Journal of cancer research and therapeutics
  28. Application of computed tomography-based radiomics analysis combined with lung cancer serum tumor markers in the identification of lung squamous cell carcinoma and lung adenocarcinoma.2024Journal of cancer research and therapeutics
  29. Guidelines for power and time variables for microwave ablation in porcine lung in vitro.2024Journal of cancer research and therapeutics
  30. Stem-like CD8 T cells in stage I lung adenocarcinoma as a prognostic biomarker: A preliminary study.2024Journal of cancer research and therapeutics
  31. Enhanced recovery after surgery for microwave ablation of lung tumors: Icing on the cake.2024Journal of cancer research and therapeutics
  32. Identifying Pathological Subtypes of Brain Metastasis from Lung Cancer Using MRI-Based Deep Learning Approach: A Multicenter Study.2024Journal of imaging informatics in medicine免费全文
  33. Chemoradiotherapy Combined with Immunotherapy in Stage III Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety Outcomes.2024Oncology
  34. Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer.2024Scientific reports免费全文
  35. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC.2024Scientific reports免费全文
  36. Dynamic prediction of lung cancer suicide risk based on meteorological factors and clinical characteristics:A landmarking analysis approach.2024Social science & medicine (1982)
  37. Safety and efficacy of percutaneous biopsy and microwave ablation in patients with pulmonary nodules on antithrombotic therapy: A study with rivaroxaban bridging.2024Thoracic cancer免费全文
  38. Differentiation of Lung Metastases Originated From Different Primary Tumors Using Radiomics Features Based on CT Imaging.2023Academic radiologyRCT
  39. Association between quantitative spectral CT parameters, Ki-67 expression, and invasiveness in lung adenocarcinoma manifesting as ground-glass nodules.2023Acta radiologica (Stockholm, Sweden : 1987)
  40. Image-guided thermal ablation for patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer.2023Asia-Pacific journal of clinical oncology
  41. Local thermal ablative therapies for extracranial oligometastatic disease of non-small-cell lung cancer.2023Asia-Pacific journal of clinical oncology
  42. Salidroside regulates tumor microenvironment of non-small cell lung cancer via Hsp70/Stub1/Foxp3 pathway in Tregs.2023BMC cancer免费全文
  43. Effect of oxycodone combined with ultrasound-guided thoracic paravertebral nerve block on postoperative analgesia in patients with lung cancer undergoing thoracoscopic surgery: protocol for a randomised controlled study.2023BMJ open免费全文
  44. Serum ferritin level is an effective prognostic factor for lung cancer immunotherapy.2023Cancer biology & therapy免费全文
  45. Orthogonal threading-through-β-sheet design of lung cancer EGFR extracellular domain-derived peptidic mimotopes binding to anti-EGFR antibody.2023Chemical biology & drug design
  46. Correlation Between Quantitative Spectral CT Parameters and Ki-67 Expression in Lung Adenocarcinomas Manifesting as Ground-glass Nodules.2023Current medical imaging
  47. A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus chemotherapy.2023European radiologyRCT免费全文
  48. Facilitating combined biopsy and percutaneous microwave ablation of pulmonary ground-glass opacities using lipiodol localisation.2023European radiology
  49. Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation.2023Frontiers in immunology免费全文
  50. Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer.2023Frontiers in immunology免费全文
  51. T lymphocyte cell: A pivotal player in lung cancer.2023Frontiers in immunology免费全文
  52. Exploration of the Long Noncoding RNAs Involved in the Crosstalk between M2 Macrophages and Tumor Metabolism in Lung Cancer.2023Genetics research免费全文
  53. Early enlarging cavitation after percutaneous microwave ablation of primary lung cancer.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  54. Synchronous computed tomography-guided percutaneous biopsy and microwave ablation for highly suspicious malignant lung ground-glass opacities adjacent to mediastinum.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  55. Changes in the pulmonary function of CT-guided microwave ablation for patients with malignant lung tumors.2023Journal of cancer research and therapeutics
  56. Lung microwave ablation: Post-procedure imaging features and evolution of pulmonary ground-glass nodule-like lung cancer.2023Journal of cancer research and therapeutics
  57. Microwave ablation for the treatment of peripheral ground-glass nodule-like lung cancer: Long-term results from a multi-center study.2023Journal of cancer research and therapeutics
  58. Immunotherapy for early-stage non-small cell lung cancer: A system review.2023Journal of cancer research and therapeutics
  59. The safety and feasibility of three-dimensional visualization planning system for CT-guided microwave ablation of stage I NSCLC (diameter ≤2.5 cm): A pilot study.2023Journal of cancer research and therapeutics
  60. Progress in the knowledge on the transformation of lung adenocarcinoma to small-cell lung cancer.2023Journal of cancer research and therapeutics
  61. SPACES: Our team's experience in lung tumor microwave ablation.2023Journal of cancer research and therapeutics
  62. Deep Learning With an Attention Mechanism for Differentiating the Origin of Brain Metastasis Using MR images.2023Journal of magnetic resonance imaging : JMRI
  63. Microwave ablation with a blunt-tip antenna for pulmonary ground-glass nodules: a retrospective, multicenter, case-control study.2023La Radiologia medica免费全文
  64. Tuberous sclerosis complex associated lymphangioleiomyomatosis.2023QJM : monthly journal of the Association of Physicians免费全文
  65. Issues and prospects of image-guided thermal ablation in the treatment of primary and metastatic lung tumors.2023Thoracic cancer免费全文
  66. PD-L1 heterogeneity in patients with non-small cell lung cancer.2022Asia-Pacific journal of clinical oncology
  67. Opposing roles of ZEB1 in the cytoplasm and nucleus control cytoskeletal assembly and YAP1 activity.2022Cell reports
  68. Prognostic Profiling of the EMT-Associated and Immunity-Related LncRNAs in Lung Squamous Cell Carcinomas.2022Cells免费全文
  69. Machine Learning-Based Radiomics for Prediction of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma.2022Disease markers免费全文
  70. Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers: long-term results.2022European radiology
  71. Computed tomography findings, associated factors, and management of pulmonary nodules in 54,326 healthy individuals.2022Journal of cancer research and therapeutics
  72. Microwave ablation of the lung: Comparison of 19G with 14G and 16G microwave antennas in ex vivo porcine lung.2022Journal of cancer research and therapeutics
  73. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.2022Journal of cancer research and therapeutics
  74. Clinical practice guidelines on image-guided thermal ablation of primary and metastatic lung tumors (2022 edition).2022Journal of cancer research and therapeutics
  75. Microwave ablation of non-small cell lung cancer tumors changes plasma levels of cytokines IL-2 and IFN-γ.2022Journal of cancer research and therapeutics
  76. Recent advances in nonsurgical treatment of pulmonary ground-glass nodules.2022Journal of cancer research and therapeutics
  77. Establishment and Validation of a Nomogram Based on Negative Lymph Nodes to Predict Survival in Postoperative Patients with non-Small Cell Lung Cancer.2022Technology in cancer research & treatment免费全文
  78. Safety and efficacy of microwave ablation for lung cancer adjacent to the interlobar fissure.2022Thoracic cancer免费全文
  79. Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis.2021Aging免费全文
  80. Multicentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-small-cell lung cancer.2021British journal of cancer免费全文
  81. Identification of a prognostic immune-related signature for small cell lung cancer.2021Cancer medicine免费全文
  82. Could concurrent biopsy and microwave ablation be reliable? Concordance between frozen section examination and final pathology in CT-guided biopsy of lung cancer.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  83. Prediction of risk of suicide death among lung cancer patients after the cancer diagnosis.2021Journal of affective disorders
  84. Effects of CT images at different reconstruction energies on radiotherapy planning of patients diagnosed with nonsmall cell lung cancer.2021Journal of cancer research and therapeutics
  85. Expert consensus on thermal ablation therapy of pulmonary subsolid nodules (2021 Edition).2021Journal of cancer research and therapeutics
  86. Computed tomography-guided percutaneous microwave ablation for pulmonary multiple ground-glass opacities.2021Journal of cancer research and therapeutics
  87. Comparison of Multi-Gene Testing Data Between Fresh and Formalin-Fixed Specimens From Core Needle Biopsy in Patients With NSCLC.2021Pathology oncology research : POR免费全文
  88. Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells.2021Science advances免费全文
  89. CT-guided microwave ablation in patients with lung metastases from breast cancer.2021Thoracic cancer免费全文
中文论文(未计入)3
  1. [Research Progress on Interleukin-6 in Screening and Prognosis of Patients 
with Non-small Cell Lung Cancer].2025Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  2. [Expert Consensus for Thermal Ablation of Pulmonary Subsolid Nodules (2021 Edition)].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  3. [Problems and prospects of image-guided thermal ablation in the treatment of primary and metastatic lung tumors].2021Zhonghua nei ke za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients邀请入组NCT06883136牵头方2025-03 启动
  2. Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance正在招募NCT06043973牵头方III期2023-09 启动
  3. Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC正在招募NCT06125041牵头方II期2023-10 启动
  4. Patient's Whole Process Follow-up Management(HOPE-1)正在招募NCT05339568牵头方2022-05 启动
  5. Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion状态不明NCT05291403牵头方不分期2022-04 启动
  6. Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer状态不明NCT04755738牵头方II期2022-01 启动
  7. Low-dose Radiotherapy Combined With Conventional Fractionated Radiotherapy in Lung Cancer After Immunotherapy Resistance状态不明NCT05906329牵头方不分期2022-12 启动
  8. First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial状态不明NCT05648071牵头方III期2021-12 启动
  9. First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial状态不明NCT05574998牵头方II期2021-02 启动
  10. A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)状态不明NCT05652712牵头方2019-01 启动
  11. Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer Patients已完成NCT05638048牵头方(推断)不分期2022-07 启动
  12. Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)正在招募NCT06809764研究中心2025-02 启动
  13. Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer已终止NCT06897579研究中心II期2025-04 启动
  14. Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)进行中,不再招募NCT06524427研究中心不分期2020-08 启动
  15. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients状态不明NCT04237805研究中心I/II期2016-11 启动
  16. Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)状态不明NCT02790190研究中心III期2015-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.2%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 4420222023: 2220232024: 1120242025: 112025

济南有 6 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胰腺癌开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科肿瘤内科风湿免疫科影像/核医学科
牵头的论文11
  1. Recent advances and treatment strategies in liver metastasis of pancreatic neuroendocrine tumors.2025Cancer metastasis reviews
  2. Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.2024Journal of cancer research and therapeutics
  3. Endogenous hyperinsulinemic hypoglycemia: case series and literature review.2023Endocrine免费全文
  4. Identification of methyltransferase modification genes associated with prognosis and immune features of pancreatic adenocarcinoma.2023Molecular and cellular probes
  5. Lutein induces an inhibitory effect on the malignant progression of pancreatic adenocarcinoma by targeting BAG3/cholesterol homeostasis.2022Journal of biochemical and molecular toxicology
  6. Pancreatic intra-arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma: A pilot study.2022Journal of cancer research and therapeutics
  7. The Association between Dietary Protein Intake and the Risk of Pancreatic Cancer: Evidence from 14 Publications.2022Nutrition and cancer
  8. The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer.2022Technology in cancer research & treatment免费全文
  9. Identification of novel candidate biomarkers for pancreatic adenocarcinoma based on TCGA cohort.2021Aging免费全文
  10. Nodules on the Lower Legs With Ankle Joint Pain.2021Gastroenterology
  11. Pancreatic carcinoma presented with panniculitis and polyarthritis: A rare case.2021Journal of cancer research and therapeutics

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 0.1%。

牵头论文
25
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 5520222023: 5520232024: 5520242025: 552025

济南有 8 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的乳腺癌开放试验。

这些数字背后的记录
论文中的科室影像/核医学科肿瘤内科普外/肝胆胰外科病理/检验科
牵头的论文25
  1. A deep learning model based on chest CT to predict benign and malignant breast masses and axillary lymph node metastasis.2025Biomolecules & biomedicine免费全文
  2. Hyperspectral Imaging for Benign and Malignant Diagnosis of Breast Tumors.2025Journal of biophotonics
  3. Complete response in a patient with metastatic metaplastic breast cancer treated with immune checkpoint inhibitor and chemotherapy: A case report and a review of the literature.2025Journal of cancer research and therapeutics
  4. Impact of postmastectomy radiotherapy on locoregional recurrence and survival in patients with ypN0 breast cancer after neoadjuvant chemotherapy: A comprehensive meta-analysis and systematic review.2025Journal of cancer research and therapeutics
  5. Predicting molecular subtypes of breast cancer based on multi-parametric MRI dataset using deep learning method.2025Magnetic resonance imaging
  6. Multimodal apparent diffusion MRI model in noninvasive evaluation of breast cancer and Ki-67 expression.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  7. Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer.2024Frontiers in immunology免费全文
  8. Non-mass-type ductal carcinoma in situ of the breast on ultrasound: Features and pathological analysis.2024Journal of cancer research and therapeutics
  9. Study on the differential diagnosis of benign and malignant breast lesions using a deep learning model based on multimodal images.2024Journal of cancer research and therapeutics
  10. Deep learning radiomics on grayscale ultrasound images assists in diagnosing benign and malignant of BI-RADS 4 lesions.2024Scientific reports免费全文
  11. Differentiation of Lung Metastases Originated From Different Primary Tumors Using Radiomics Features Based on CT Imaging.2023Academic radiologyRCT
  12. Evaluation of breast cancer malignancy, prognostic factors and molecular subtypes using a continuous-time random-walk MR diffusion model.2023European journal of radiology
  13. PKCζ phosphorylates VASP to mediate chemotaxis in breast cancer cells.2023Experimental cell research
  14. The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.2023Frontiers in immunology免费全文
  15. Deep Learning With an Attention Mechanism for Differentiating the Origin of Brain Metastasis Using MR images.2023Journal of magnetic resonance imaging : JMRI
  16. Effects of exercise on inflammatory factors and IGF system in breast cancer survivors: a meta-analysis.2022BMC women's health免费全文
  17. p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer.2022Cancer investigation
  18. Modality-correlation embedding model for breast tumor diagnosis with mammography and ultrasound images.2022Computers in biology and medicine
  19. The Anti-Breast Cancer Activity of Dihydroartemisinin-5-methylisatin Hybrids Tethered via Different Carbon Spacers.2022Molecules (Basel, Switzerland)免费全文
  20. Postmastectomy Radiotherapy Improves Survival Benefits in De Novo Stage IV Breast Cancer: A Propensity-Score Matched Analysis.2022Technology in cancer research & treatment免费全文
  21. Mediation of circ_RPPH1 on miR-146b-3p/E2F2 pathway to hinder the growth and metastasis of breast carcinoma cells.2021Aging免费全文
  22. LRSCnet: Local Reference Semantic Code learning for breast tumor classification in ultrasound images.2021Biomedical engineering online免费全文
  23. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.2021Frontiers in immunology免费全文
  24. Giant epidermal inclusion cyst with infection arising within the breast parenchyma: a case report.2021The Journal of international medical research免费全文
  25. CT-guided microwave ablation in patients with lung metastases from breast cancer.2021Thoracic cancer免费全文
中文论文(未计入)1
  1. [A giant malignant phyllodes tumor of the breast: a case report].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Follow up Study of Crocin on Cardiac Function Protection in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy Based on Color Doppler Ultrasound Combined With Myocardial Zymogram状态不明NCT06187818牵头方(推断)2023-09 启动
  2. Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer Patients已完成NCT05638048牵头方(推断)不分期2022-07 启动
  3. Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer:an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy状态不明NCT05636644牵头方(推断)2022-11 启动
  4. A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer已完成NCT05945927研究中心2023-09 启动
  5. GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer已完成NCT05054751研究中心III期2021-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胶质瘤

Glioma

2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.2%。

牵头论文
14
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 6620232024: 2220242025: 332025

济南有 5 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。

这些数字背后的记录
论文中的科室神经外科影像/核医学科神经内科

这些论文过半是实验室或动物研究。

牵头的论文14
  1. PDIA3 Inhibition Facilitates Sensitivity of IKE-Induced Ferroptosis via STAT3/LCN2 Axis to Improve Glioblastoma Therapy.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis.2025Cancer research
  3. PYCR1 expresses in cancer-associated fibroblasts and accelerates the progression of C6 glioblastoma.2025Histology and histopathology
  4. Bioinformatics prediction and experimental verification identify B4GALT1 as a diagnostic biomarker of glioblastoma.2025International journal of biological macromolecules
  5. TRIM56: a promising prognostic immune biomarker for glioma revealed by pan-cancer and single-cell analysis.2024Frontiers in immunology免费全文
  6. Deep learning models for predicting the survival of patients with medulloblastoma based on a surveillance, epidemiology, and end results analysis.2024Scientific reports免费全文
  7. Integrated Bioinformatic Analysis of the Correlation of HOXA10 Expression with Survival and Immune Cell Infiltration in Lower Grade Glioma.2023Biochemical genetics
  8. N6-Methyladenosine-modified lncRNA LINREP promotes Glioblastoma progression by recruiting the PTBP1/HuR complex.2023Cell death and differentiation免费全文
  9. Re: Effect of glioma-derived immunoglobulin on biological function of glioma cells: The emerging roles of immunoglobulins in the tumor immune microenvironment.2023European journal of cancer (Oxford, England : 1990)
  10. Discrimination Between Glioblastoma and Solitary Brain Metastasis Using Conventional MRI and Diffusion-Weighted Imaging Based on a Deep Learning Algorithm.2023Journal of digital imaging免费全文
  11. Cytokines/chemokines and immune checkpoint molecules in anti-leucine-rich glioma-inactivated 1 encephalitis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  12. Using the metabolite alterations monitoring the AEG-1 expression level and cell biological behaviour of U251 cell in vitro.2023PloS one免费全文
  13. Identification of key genes involved in the recurrence of glioblastoma multiforme using weighted gene co-expression network analysis and differential expression analysis.2021Bioengineered免费全文
  14. Hsa_circ_0001017 inhibits proliferation and metastasis via regulating the let-7g-3p/NDST3 axis in glioma.2021Folia neuropathologica

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

济南有 4 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文1
  1. SOX7 modulates the progression of hepatoblastoma through the regulation of Wnt/β-catenin signaling pathway.2022Journal of cancer research and therapeutics
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor状态不明NCT02933333研究中心IV期2016-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 8 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Association of rs11801299 and rs1380576 polymorphisms at MDM4 with risk, clinicopathological features and prognosis in patients with retinoblastoma.2019Cancer epidemiology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor状态不明NCT02933333研究中心IV期2016-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

济南有 18 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

济南有 8 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文1
  1. FTO inhibits oxidative stress by mediating m6A demethylation of Nrf2 to alleviate cerebral ischemia/reperfusion injury.2023Journal of physiology and biochemistry
早期论文(2016–2020 年)1
  1. MiR-424 suppressed viability and invasion by targeting to the DCLK1 in neuroblastoma.2020European review for medical and pharmacological sciences
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor状态不明NCT02933333研究中心IV期2016-09 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.1%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

济南有 7 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.2%。

牵头论文
6
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 0020242025: 332025

济南有 4 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的淋巴瘤开放试验。

这些数字背后的记录
论文中的科室儿科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

济南有 3 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

济南有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 11 篇,占 2.2%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 1120232024: 1120242025: 442025

济南有 4 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    分期
    II/III期
    开始
    2024-07
    发布
    登记号
    NCT06447597

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、遵义、长春、长沙

  2. 正在招募
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    分期
    III期
    开始
    2021-07
    发布
    登记号
    NCT04951622

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题危象与重症监护抗体与诊断胸腺与胸腺切除
论文中的科室神经内科

这些论文过半是实验室或动物研究。

牵头的论文11
  1. Phenotypic and functional dysregulations of CD8 + T Cells in myasthenia gravis.2025Clinical and experimental medicine免费全文
  2. Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review.2025Frontiers in immunology免费全文
  3. Resveratrol-A Herbal Immunomodulator, Ameliorates Experimental Autoimmune Myasthenia Gravis by Regulating the Foxo1-Foxp3 Pathway.2025Journal of biochemical and molecular toxicology
  4. Diabetes exacerbates myasthenia gravis by enhancing pathological thymic output via the GPR183-7α,25-OHC axis.2025Journal of neuroinflammation免费全文
  5. Dihydroartemisinin ameliorates experimental autoimmune myasthenia gravis by regulating CD4+ T cells and modulating gut microbiota.2024International immunopharmacology
  6. Extracellular vesicles encapsulated with caspase-1 inhibitor ameliorate experimental autoimmune myasthenia gravis through targeting macrophages.2023Journal of controlled release : official journal of the Controlled Release Society
  7. Myasthenia gravis: The pharmacological basis of traditional Chinese medicine for its clinical application.2022BioFactors (Oxford, England)
  8. Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells.2022Clinical immunology (Orlando, Fla.)
  9. Natural killer cells promote the differentiation of follicular helper T cells instead of inducing apoptosis in myasthenia gravis.2021International immunopharmacology
  10. Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells.2021International immunopharmacology
  11. Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis via modulating both adaptive and innate immunity.2021Journal of neuroinflammation免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.正在招募NCT06447597研究中心II/III期2024-07 启动
  2. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis正在招募NCT04951622研究中心III期2021-07 启动
  3. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis已终止NCT04963270研究中心III期2021-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

济南有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流血管重建手术遗传
论文中的科室影像/核医学科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.2%。

牵头论文
8
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 3320222023: 0020232024: 0020242025: 112025

济南有 6 家医院列在冠心病下全国有 231 家医院列在冠心病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的冠心病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科
牵头的论文8
  1. C/EBPβ-Lin28a positive feedback loop triggered by C/EBPβ hypomethylation enhances the proliferation and migration of vascular smooth muscle cells in restenosis.2025Chinese medical journal免费全文
  2. Wrist pulse diagnosis of stable coronary heart disease based on acoustics waveforms.2022Computer methods and programs in biomedicine
  3. Recurrent type III Kounis syndrome: coronary artery inflammation assessed by 18F-fluorodeoxyglucose positron emission tomography/computer tomography.2022European heart journal. Cardiovascular Imaging
  4. Multi-trajectories of systolic and diastolic hypertension and coronary heart disease in middle-aged and older adults.2022Frontiers in public health免费全文
  5. Methylenetetrahydrofolate Reductase Gene Polymorphism C677T is Associated with Increased Risk of Coronary Heart Disease in Chinese Type 2 Diabetic Patients.2021Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  6. A cohort study on risk factors of high-density lipoprotein cholesterol hypolipidemia among urban Chinese adults.2021Lipids in health and disease免费全文
  7. Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes.2021Medicine免费全文
  8. Cardiac cephalalgia closely associated with acute myocardial infarction.2021The American journal of emergency medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Modified Dynamic Needle Tip Positioning vs Conventional Long-axis In-plane in Radial Artery Cannulation已完成NCT05687370牵头方不分期2023-01 启动
  2. Hemodynamic Effect of Topical Anesthesia During Induction in Patients Undergoing Cardiac Surgery已完成NCT05323786牵头方不分期2022-04 启动
  3. Effect of Topical Anesthesia on Hemodynamics During the Induction Period in Patients Undergo Cardiac Surgery.已完成NCT04744480牵头方不分期2021-03 启动
  4. Comparison of Dexmedetomidine and Meperidine for the Prevention of Shivering Following Coronary Artery Bypass Graft状态不明NCT04735965牵头方IV期2021-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 1120242025: 222025

济南有 4 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录
论文中的科室神经内科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊柱侧弯

Scoliosis

2021–2025 年中国大陆作者发表的 925 篇脊柱侧弯 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

济南有 3 家医院列在脊柱侧弯下全国有 107 家医院列在脊柱侧弯下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的脊柱侧弯开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 0020232024: 0020242025: 002025

济南有 5 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科神经外科
牵头的论文4
  1. Increased formation of neutrophil extracellular traps in patients with anti-N-methyl-d-aspartate receptor encephalitis.2022Frontiers in immunology免费全文
  2. Coexistence of NMDAR, GAD65, and SOX1 antibody-associated autoimmune encephalitis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. Recurrent anti-AMPA receptor encephalitis associated with thymus cancer.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Long-term follow-up of a child with anti-AMPA receptor encephalitis.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

济南有 2 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

济南有 8 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    发布
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. A Phase I Study of HW241045 in Healthy Subjects即将招募NCT07593690研究中心I期2026-06 启动
  3. A Trial of SHR - 1906 in Healthy Subjects已完成NCT04986540研究中心I期2021-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 1 篇,占 2.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

济南有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 27 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录
牵头的论文1
  1. Tuberous sclerosis complex associated lymphangioleiomyomatosis.2023QJM : monthly journal of the Association of Physicians免费全文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

济南有 8 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室影像/核医学科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

济南有 3 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

济南有 9 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文1
  1. BAFF in autoimmune kidney diseases: pathogenic pathways, biomarker potential, and therapeutic horizons.2025Renal failure免费全文
早期论文(2016–2020 年)1
  1. Increasing prevalence of membranous nephropathy in patients with primary glomerular diseases: A cross-sectional study in China.2017Nephrology (Carlton, Vic.)
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  2. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  3. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 1 家医院列在戈谢病下全国有 40 家医院列在戈谢病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Development of a human iPSC line (SMBCi004-A) from a patient with Gaucher disease.2020Stem cell research

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

济南有 2 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年没有牵头遗传性血管性水肿的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 2 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China已完成NCT06346899研究中心2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

山东第一医科大学第一附属医院(山东省千佛山医院)

First Affiliated Hospital of Shandong First Medical University

济南

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Shandong Provincial Qianfoshan Hospital; Qianfoshan Hospital Affiliated to Shandong University; Qianfoshan Hospital; Shandong Qianfoshan Hospital; Qianfoshan Hospital Affiliated with Shandong University; Shandong Qianfoshan Hospital Affiliated With Shandong University; Shandong Qianfoshan Hospital Affiliated to Shandong University; first affiliated hospital of Shandong First medical university

提出更正下载数据